Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

Genentech, a member of the Roche Group and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab), in combination with corticosteroids, as a new medicine for adults with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA).

20 Apr 2011

Positive interim anemia response data from YM's CYT387 Phase I/II trial in myelofibrosis

YM BioSciences Inc., today announced that updated interim anemia response data were reported for the first 60 patients enrolled in the Phase I/II trial of its JAK1/JAK2 inhibitor, CYT387, for the treatment of myelofibrosis.

19 Apr 2011

Seattle enters second ADC research collaboration agreement with Genmab

Genmab A/S and Seattle Genetics, Inc. announced today that the companies have entered into a second antibody-drug conjugate research collaboration agreement.

19 Apr 2011

Single antibody injection limits tissue and organ destruction after ischaemic events

Medical researchers today held out promise that a simple injection is being developed to limit the devastating consequences of heart attacks and strokes.

19 Apr 2011

Journal of Clinical Oncology publishes CytRx tamibarotene Phase 2b trial results in APL

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the publication of a case report in the peer-reviewed Journal of Clinical Oncology documenting the use of tamibarotene in the successful treatment of a patient with recurrent advanced-stage acute promyelocytic leukemia.

19 Apr 2011

Amylin reports total revenue of $152.7 million for quarter ended March 31, 2011

Amylin Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2011.

18 Apr 2011

CHMP adopts EU positive opinion for TYSABRI labeling with anti-JCV antibody status

Biogen Idec and Elan Corporation, plc today announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion for inclusion of an additional risk factor, anti-JC virus (JCV) antibody status, to the product label for TYSABRI in the European Union.

18 Apr 2011

New JAMA issue focuses on infectious diseases and immunology

Several media outlets report on findings published in this week's issue of JAMA, which focuses on infectious diseases and immunology.

15 Apr 2011

Genzyme reports positive data from 5-year alemtuzumab Phase 2 study in MS

Genzyme Corp., a subsidiary of sanofi-aventis Group, today reported additional five-year patient data from its completed Phase 2 multiple sclerosis (MS) trial showing that nearly two-thirds of alemtuzumab treated patients remained free of clinically-active disease as much as four years after most patients received their last course of the investigational drug.

15 Apr 2011

Donor-specific antibodies may accelerate arteriosclerosis after kidney transplantation

Kidney transplant recipients who develop antibodies in response to receiving new organs can develop accelerated arteriosclerosis, or narrowing of the arteries that supply blood to the kidney, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results indicate that arteriosclerosis resulting from such donor-specific antibodies may play an important role in organ rejection following transplantation.

15 Apr 2011

Quest PharmaTech, Hemispherx Biopharma enter clinical development arrangement

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced a clinical development arrangement with U.S. based Hemispherx Biopharma Inc. to evaluate the clinical utility of combining Quest's antibody immunotherapy technology with Hemispherx's immune activator in a thirty patient clinical trial.

15 Apr 2011

SQI enters clinical validation agreement with University North Carolina Kidney Center for Vasculitis Assay

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based autoimmune biomarker testing, today announced it entered into a clinical validation agreement with University North Carolina Kidney Center, Chapel Hill, to evaluate SQI's new multiplexed, automated approach for biomarker detection in vasculitis.

15 Apr 2011

NRC, NCKU partner to develop cancer diagnostic and treatment technologies

A Taiwanese research team led by Prof. Dar-Bin Shieh of Institute of Oral Medicine in Medical College at National Cheng Kung University has partnered with a research group led by Dr. Dennis Whitefield from National Research Council of Canada to develop innovative cancer diagnostic and treatment technologies.

15 Apr 2011

Early uMSC transplantation may treat lupus nephritis

Human umbilical cord blood-derived mensenchymal stem cells have been found to offer benefits for treating lupus nephritis when transplanted into mouse models of systemic lupus erythematosus.

12 Apr 2011

Study shows neutralizing antibodies to C5a protein may prevent heart failure

New research published online in The FASEB Journal details research in rats and mice that offers hope for stopping the devastating, and often fatal, effects of sepsis in humans. In the study, University of Michigan researchers show how neutralizing the effects of a key protein fragment, called C5a, used by the immune system to attract white blood cells may ultimately prevent heart failure.

12 Apr 2011

NCI awards MabVax with Phase II SBIR grant to develop vaccine against recurrent sarcoma

MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received the Phase 2 portion of the Small Business Innovation Research Grant from the National Cancer Institute under the agency's Streamlined Non-competing Award Procedures.

11 Apr 2011

GeoVax Labs expands its HIV/AIDS vaccine program with NIAID, NIH and HVTN

GeoVax Labs, Inc., announced today that it is expanding its preventative HIV/AIDS vaccine development effort in collaboration with the National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health and the HIV Vaccine Trials Network.

11 Apr 2011

Merck announces interim analysis from V710 Phase II/III trial in S. aureus infection

Merck, known as MSD outside the United States and Canada, and Intercell AG today announced that following a pre-specified interim analysis from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus infection, the independent Data Monitoring Committee recommended suspension of enrollment.

11 Apr 2011

New dengue test receives FDA marketing clearance

The U.S. Food and Drug Administration today allowed marketing of the first test to help diagnose people with signs and symptoms of dengue fever or dengue hemorrhagic fever, a leading cause of illness and death in the tropics and subtropics.

11 Apr 2011

GeoVax Labs to update its HIV/AIDS vaccine status at World Vaccine Conference

Harriet Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc., will provide an update on the status of the Company's therapeutic and preventative HIV vaccines at the 2011 World Vaccine Conference at the Gaylord National Hotel and Convention Center in Washington DC on Thursday, April 14.

8 Apr 2011

Antibody News and Research

Further Reading

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

Positive interim anemia response data from YM's CYT387 Phase I/II trial in myelofibrosis

Seattle enters second ADC research collaboration agreement with Genmab

Single antibody injection limits tissue and organ destruction after ischaemic events

Journal of Clinical Oncology publishes CytRx tamibarotene Phase 2b trial results in APL

Amylin reports total revenue of $152.7 million for quarter ended March 31, 2011

CHMP adopts EU positive opinion for TYSABRI labeling with anti-JCV antibody status

New JAMA issue focuses on infectious diseases and immunology

Genzyme reports positive data from 5-year alemtuzumab Phase 2 study in MS

Donor-specific antibodies may accelerate arteriosclerosis after kidney transplantation

Quest PharmaTech, Hemispherx Biopharma enter clinical development arrangement

SQI enters clinical validation agreement with University North Carolina Kidney Center for Vasculitis Assay

NRC, NCKU partner to develop cancer diagnostic and treatment technologies

Early uMSC transplantation may treat lupus nephritis

Study shows neutralizing antibodies to C5a protein may prevent heart failure

NCI awards MabVax with Phase II SBIR grant to develop vaccine against recurrent sarcoma

GeoVax Labs expands its HIV/AIDS vaccine program with NIAID, NIH and HVTN

Merck announces interim analysis from V710 Phase II/III trial in S. aureus infection

New dengue test receives FDA marketing clearance

GeoVax Labs to update its HIV/AIDS vaccine status at World Vaccine Conference

Monoclonal Antibody Manufacturing Trends eBook eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News